Israel Englander’s Teva Pharmaceuticals TEVA Stock Holding History

Israel Englander’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$898K	Buy	26,500 +10,700	+68%	+$356K	﹤0.01%	4382
2026 Q1	$476K	Sell	15,800 -21,500	-58%	-$692K	﹤0.01%	4796
2025 Q4	$1.16M	Sell	37,300 -534,200	-93%	-$13.2M	﹤0.01%	4384
2025 Q3	$11.5M	Buy	571,500 +472,000	+474%	+$8.29M	﹤0.01%	2241
2025 Q2	$1.67M	Sell	99,500 -60,400	-38%	-$975K	﹤0.01%	4031
2025 Q1	$2.46M	Sell	159,900 -41,800	-21%	-$747K	﹤0.01%	3585
2024 Q4	$4.45M	Buy	201,700 +176,300	+694%	+$3.21M	﹤0.01%	2921
2024 Q3	$458K	Sell	25,400 -23,300	-48%	-$408K	﹤0.01%	4902
2024 Q2	$791K	Sell	48,700 -209,400	-81%	-$3.23M	﹤0.01%	4271
2024 Q1	$3.64M	Sell	258,100 -639,300	-71%	-$8.06M	﹤0.01%	3198
2023 Q4	$9.37M	Buy	897,400 +500,000	+126%	+$4.67M	﹤0.01%	2253
2023 Q3	$4.05M	Sell	397,400 -734,000	-65%	-$6.83M	﹤0.01%	2896
2023 Q2	$8.52M	Buy	1,131,400 +714,200	+171%	+$5.79M	﹤0.01%	2172
2023 Q1	$3.69M	Buy	417,200 +119,100	+40%	+$1.18M	﹤0.01%	2884
2022 Q4	$2.72M	Sell	298,100 -160,100	-35%	-$1.4M	﹤0.01%	3305
2022 Q3	$3.7M	Sell	458,200 -241,800	-35%	-$2.14M	﹤0.01%	3181
2022 Q2	$5.26M	Sell	700,000 -1,600,000	-70%	-$13.9M	﹤0.01%	2754
2022 Q1	$21.6M	Sell	2,300,000 -500,000	-18%	-$4.17M	0.01%	1316
2021 Q4	$22.4M	Buy	2,800,000 +1,600,000	+133%	+$14.4M	0.01%	1329
2021 Q3	$11.7M	Buy	1,200,000 +490,000	+69%	+$4.59M	0.01%	1868
2021 Q2	$7.03M	Sell	710,000 -546,400	-43%	-$5.78M	﹤0.01%	2318
2021 Q1	$14.5M	Buy	+1,256,400	New	+$14.4M	0.01%	1400
2020 Q1	–	Sell	-1,300,000	Closed	-$12.7M	–	4464
2019 Q4	$12.7M	Sell	1,300,000 -1,757,500	-57%	-$15.7M	0.02%	1175
2019 Q3	$21M	Buy	+3,057,500	New	+$23.4M	0.03%	744
2017 Q1	–	Sell	-650,000	Closed	-$23.6M	–	3830
2016 Q4	$23.6M	Buy	+650,000	New	+$26M	0.05%	534
2014 Q1	–	Sell	-47,400	Closed	-$1.9M	–	3871
2013 Q4	$1.9M	Sell	47,400 -9,900	-17%	-$390K	0.01%	1868
2013 Q3	$2.17M	Sell	57,300 -15,300	-21%	-$597K	0.01%	1639
2013 Q2	$2.85M	Buy	+72,600	New	+$2.83M	0.01%	1370

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Israel Englander's TEVA Position: Q2 2026 in Review

Israel Englander increased its Teva Pharmaceuticals (TEVA) stake by 72% in Q2 2026, buying an estimated $45.7M and bringing the position to 3,265,321 shares worth $111M. The position accounts for 0.04% of the portfolio, ranked #465.

Israel Englander first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $560M in Q1 2015. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Israel Englander held 3,265,321 shares of Teva Pharmaceuticals worth $111M as of Q2 2026.
Israel Englander bought 1,371,476 Teva Pharmaceuticals shares in Q2 2026, an estimated $45.7M.
Teva Pharmaceuticals made up 0.04% of Israel Englander's portfolio in Q2 2026, its #465 holding.
Israel Englander first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Israel Englander's Teva Pharmaceuticals position peaked at $560M in Q1 2015.
671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.